Explore new treatment options for early NSCLC: efficacy and safety assessment of pulmonary ectoptomy
1. Explore new treatment options for early NSCLC: efficacy and safety assessment of pulmonary ectomy
The study included around-the-board NSCLC patients with a small IA stage, of whom 576 were subjected to pulmonary folic circumcision and 529 to pulmonary ectomy. After 7.3 years of medium follow-up.
The results show that patients with upper left-leaf tumours have a significantly better survival rate than pneumoctomy groups, with OS and RFS having 95.2 per cent and 91.0 per cent respectively for five years, compared to 86.0 per cent and 78.6 per cent, respectively. In short, pulmonary ectomy can be used as an effective treatment in early NSCLC treatments.
Click to read original
2. Post-pregnative effects of the decomposition of small-cell lung cancer induction therapy
The retrospective study selected small-cell lung cancer patients who received standardised treatment at Wuhan University Central-South Hospital from January 2013 to June 2021 and who had a full image of them, to map the size of the tumor before and after induction to chemotherapy through the image system, and to calculate the relief depth of induction to chemotherapy. The Cox risk ratio model was used for multi-factor analysis using the best prognosis indicators and their predictions of time-dependent job characteristics (time-dependent timeROC) for small-cell lung cancer in the Evaluation Bureau.
The timeROC results show that the size of the post-inducing chemoplasm tumour residue is the best predictive indicator for a patient to survive without progress for a year [AUT) = 0.86, 95% CI: 0.78~0.94] and 2 years of total survival (AUC = 0.76, 95% CI:0.65~0.87). Multiple-factor analysis shows that the absolute value of the post-inducing tumour mass is an independent factor (all P<0.001) that affects the Bureau ' s limited-term non-progressive survival of small cell lung cancer (HR=1.006, 95CI:1.003~1.009) and total survival (HR=1.009, 95% CI:1.005~1.012). Inducing tumours to recede to less than 10 cm after chemotherapy, regardless of their initial tumour load, can achieve better long-term tumour preparation. In general, the decomposition depth of small-cell induction of lung cancer in the Bureau can predict its long-term effects and provide individualized treatment guidance to patients.
Click to read original
Lancet’s sub-pubration of late-stage colon cancer transformation strategy: New Auxiliary chemotherapy or new Auxiliary chemotherapy?
The study included LACC patients who were initially inoperable and were assigned randomly to NACT (control group, n = 20) and NACHR (research group, n = 25). The NACT group receives the XELOX programme (Osharipine 130 mg/m2, qd, d1, q3w; Capitabin 1000 mg/m2, Bid, d1~d14, q3w) with four cycles of treatment. In addition to chemotherapy, the NART group receives extra daily treatment (GTV 45 ~50 Gy/25 F; CTV 42.5 ~45 Gy/25 F), while the NACRT group uses the mXELOX programme, of which Osharipine received a dose of 100 mg/m2. If the patient is converted to excised LACC, 6-12 weeks of surgery after the new assisted treatment is planned and assisted chemotherapy is provided.
The results showed a three-year OS rate of 87.6 per cent vs. 75.0 per cent for NART and NACT, respectively. In any case, for partially terminal colon cancers that cannot be excised at first, the NACT strategy, as opposed to the NACT strategy, increases the R0 cision rate, prolongs PFS and may improve OS.
Click to read original
4. Consensus of Chinese experts on target orientation and co-alignment with immunization drugs for local advanced cervical cancer
Synchronized chemotherapy is the combination of radiation and chemotherapy treatment, with a small dose of chemotherapy to increase the effectiveness of radiotherapy treatment to reduce the recurrence and transfer of tumours and improve patient prognosis. At present, the main basis for the increased sensitivity of synchronotherapy is that synchronous chemotherapy prevents the repair of tumour cells; chemotherapy and tumour cells function in different cycles and act in a synergistic manner. However, even for partially advanced cervical cancer (LACC) patients with synchronised chemotherapy, the five-year survival rate is only 60 per cent, which is not ideal. In order to improve the treatment effectiveness of LAC patients, researchers have conducted a series of drug-exploration studies, including combination-target drugs, immunopharmaceutical drugs and new assistive treatments. While targeted or immuno-pharmaceutical drugs are an effective means of treating cervical cancer, there is still a lack of evidence-based evidence on a large scale and there is still a need for multi-centre, forward-looking and random phase III clinical research to raise the level of evidence-based medicine. The Consensus summarizes a number of key published evidence-based medical evidence, in particular progress in target and immunization clinical research, to inform national counterparts.
Click to read original
5. Expert consensus on neuroendocrine tumours in the lung and breast of China (2021)
Pulmonary and breast neuroendocrine tumours (NENS) are rare tumours, according to the WHO breast tumour pathology classification, version 5, published in 2021, and lung and breast NENS include typical, non-typical, large-cell neuroendocrine and small-cell cancers. Despite the gradual increase in the incidence of NENs in the lungs and breast in recent years, there is a lack of random control of clinical findings for NENs at home and abroad to guide clinical practice. The treatment of early pulmonary and breast NENs is surgically complete, and the treatment of non-excised late-stage diseases includes medication, cytin and local treatments. In order to further improve the standard level of treatment of NENs in the lung and breast, the Committee of Experts on Neural Endocrinological Oncology of the Chinese Society of Clinical Oncology developed a consensus of Chinese experts on neuroendocrine on lung and breast endocrine on the basis of available clinical research evidence at home and abroad, in conjunction with international guidelines and after multidisciplinary expert discussions. The consensus includes epidemiology, diagnosis, pathological classification, phasing and treatment and follow-up of lung and thymus NENs (except for small cell lung cancer).
Click to read original
6×4! Comparative analysis of DRVd and traditional triple therapy RVd in newly diagnosed patients with multiple osteoporosis
The study included 1,000 NDM patients receiving RRVd treatment and 326 NDM patients receiving DRVd treatment. The research data are assessed through the IMWG standard for unified response. The genetic risk stratification of patients is based on the definition of IMWG and is tested by fluorescent in situ (FISH) or mid-term cytogenetics.
An analysis of the results of the treatment shows that the overall relief (ORR) for DRVd patients following induction treatment is higher than for RWd (99.6 per cent vs. 97.1 per cent); and the very good partial relief (VVGR) rate is also significantly better in DRVd (86.5 per cent vs. 67.6 per cent). After receiving a stem cell transplant (ASCT), the DRVd group had 99.2% ORR, the RWd group had 98.6% and the DRVd group ‘ s VGPR rate had increased further to 95.6%. In short, DRVd has demonstrated better efficacy than NVd among NDM patients as induction treatment.
Click to read original
Professor Lee Jin Woo’s team: BCMA/GRRC5D Double Differentity CAR-T cell therapy or potential treatment options for R/RMM
The study included R/R MM patients aged 18-75 years who performed at levels 0-3 in the Eastern Cooperative Oncology Group. At the dose increment stage, the BCMA/GRPC5D dichotomous CAR-T cells received 0.5 x 106/kg, 1.0 x 106/kg, 2.0 x 106/kg and 4.0 x 106/kg CAR-T cells, respectively, and more MM patients were included at the dose extension stage at the selected dose.
The results showed that at a dose of 4.0 x 106/kg CAR-T-cells, two cases of R/RMM patients had a dose-restrictive toxicity response, one of which had been caused by submono hemorrhage (not considered to be related to research treatment). The maximum tolerance dose was determined to be 2.0 x 106/kg CAR-T cells. In summary, BCMA/GRPC5D dual-specific CAR-T-cell therapy shows good safety and encouraging activity among R/RMM patients.
